Navigation Links
Spherix Elects New Independent Director, and Elects Chairman of the Board
Date:5/14/2009

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that, on May 12, 2009, its Board of Directors elected a new, independent Director, Thomas B. Peter, to begin serving immediately. Mr. Peter will also serve on the Company's Compensation and Nominating Committees.

Spherix's Nominating Committee selected Mr. Peter based on his lengthy career in the pharmaceutical industry, including direct experience with Avandia, a diabetes drug. Mr. Peter has spent more than 33 years working at GlaxoSmithKline, where he was most recently a Regional Vice President. He also held numerous positions across the sales and marketing functions, and was actively involved in the promotion of Avandia and the subsequent combinations of Avandia with metformin and a sulfonylurea from the time of their respective market introductions.

With the election of Mr. Peter to Spherix's Board, the Company has notified NASDAQ that it has regained compliance with NASDAQ's rule that requires a majority of the board of directors be independent directors.

In related news, Spherix's Board also elected Dr. Robert J. Vander Zanden as its Chairman of the Board. Dr. Vander Zanden was previously elected Interim Chairman following the death of its former Chairman, A. Paul Cox, Jr., earlier this year. Dr. Vander Zanden joined the Board in 2004 following his retirement from Kraft Foods International, after having served in two Vice President positions.

"We are very pleased with the election of Tom Peter to our Board of Directors and are confident that his particular background will be extremely helpful as we prepare for the potential commercialization of Naturlose(R) as a treatment for type 2 diabetes," said Dr. Claire Kruger, Chief Executive Officer of Spherix. "Dr. Vander Zanden's historical knowledge of the Company, along with his distinguished career in technical and business aspects of the food science industry, make him the perfect choice for the Chairman position."

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries--Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
2. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
3. Spherix D-tagatose to be Supplied by Inalco SpA
4. Growth Achieved in Spherixs Health Sciences Consulting Business
5. Spherix Reports Second Quarter Earnings
6. University of California Los Angeles Selects Velos eResearch
7. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
8. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
9. Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
10. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
11. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , January 17, 2017 ... 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... recently in European Neurological Review ... Catherine Amey reports that despite standard ...
(Date:1/17/2017)... January 17, 2017 Transparency Market Research has ... Acid, Sodium Benzoate, Benzyl Alcohol and Others) Market - Global Industry ... report, the global benzaldehyde derivative market was valued at ... 2.14 Bn by 2024, expanding at a CAGR of 5.1 % ... ...
(Date:1/17/2017)... DUBLIN and BUDAPEST, Hungary , ... ) and Gedeon Richter Plc. today announced positive results from ... trials evaluating the efficacy and safety of ulipristal acetate in ... drug application filing for ulipristal acetate is planned for the ... the favorable results of Venus II supporting the efficacy and ...
Breaking Medicine Technology:
(Date:1/16/2017)... Grove Village, IL (PRWEB) , ... January 16, ... ... and personal audio products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs ... and Convention Center in Las Vegas, Booth #2809. The SHOT Show is the ...
(Date:1/16/2017)... ... January 16, 2017 , ... As New York’s fastest growing ... MD to their medical staff, according to eye surgeon, Jeffrey Martin, MD, FACS, ... a division of SightMD. Dr. Giamos will practice primarily out of SightMD’s Riverhead, ...
(Date:1/16/2017)... , ... January 16, 2017 , ... St. Louisans are well-aware of the following facts ... This year’s influenza shot seems to be having no effect on keeping this particularly ... half of the people around are coughing, sneezing, or sniffling , These ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all types of ... test for, as well. The money spent screening for and treating cancer in the ... screen patients for cancer more than in any other country that has an advanced ...
(Date:1/15/2017)... , ... January 15, 2017 , ... In this role, ... the United States for the asthma & allergy friendly mark. This certification program was ... test and identify consumer products to be more suitable for the 60+ million people ...
Breaking Medicine News(10 mins):